Axial Spondyloarthritis Market Analysis and Forecast, 2022-2032

1
Axial Spondyloarthritis Market -
res
A Global and Country Analysis
Table of Content
Focus on Commercialized Therapies, Potential
Pipeline Products, Indication, and
Country Analysis and Forecast 2022-2032 May 2022
t e k r a M s i t i r h t r a o l y d n o
p S l a i x All rights reserved at BIS
Research Inc. 1 A
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
Copyright 2022 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
2
3

• Table of Content
• Executive Summary.................................
  .........................................17
• 1. Market ........................................
  ...............................................23
• 1.1 Product Definition............................
  ..................................................
  ..............24
• 1.1.1 Radiographic Axial Spondyloarthritis
  ..................................................
  .....24
• 1.1.2 Non-radiographic Axial Spondyloarthritis
  (nr-axSpA) ............................24 1.1.3
  Inclusion and Exclusion ........................
  ..................................................
  ...24
• 1.2 Market Scope .................................
  ..................................................
  ................25 1.2.1 Key Questions Answered
  in the Report ....................................
  ................26 1.3 Research Methodology
  ..................................................
  .................................27
• 1.3.1 Global Axial Spondyloarthritis Market
  Research Methodology .............27 1.3.2 Data
  Sources ..........................................
  ..................................................
  ...28 1.3.2.1 Primary Data Sources...............
  ..................................................
  ....................... 28
• 1.3.2.2 Secondary Data Sources....................
  ..................................................
  ............. 29
• 1.3.3 Market Estimation Model
  ..................................................
  ..........................29
• 1.3.4 Criteria for Company Profiling
  ..................................................
  .................31
• 1.4 Market Overview ..............................
  ..................................................
  ..............32
• 1.4.1 Introduction .............................
  ..................................................
  ..................32
• 1.4.2 Current Market Size and Growth Potential,
  Million, 2021-2032..............32
• 1.4.3 Disease Background .......................
  ..................................................
  ..........33
• 1.4.4 Treatment Plan............................
  ..................................................
  ...............35
• 1.4.4.1 Tumor Necrosis Factor (TNF) Inhibitors
  ..................................................
  .......... 36
• 1.4.4.2 Interleukin (IL)-17 Inhibitors
  ..................................................
  ............................. 37
• 1.4.4.3 Janus Kinase (JAK) Inhibitors.............
  ..................................................
  ............. 38

Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
3
4

• 1.4.6.2 Epidemiology of Axial Spondyloarthritis
  (Germany, France, Italy, and Spain
• (EU4) U.K.) ....................................
  ..................................................
  ............... 45
• 1.4.6.3 Japan Epidemiology of Axial
  Spondyloarthritis ................................
  .................. 47
• 1.4.7 Pipeline Analysis .........................
  ..................................................
  ..............48
• 1.4.7.1 By Clinical Phase.........................
  ..................................................
  .................... 48
• Impact of COVID-19 on Global Axial
  Spondyloarthritis Market ...............49
• Interruption in Research and Clinical Development
  and Commercial Operation ........................
  ..................................................
  ................................. 49
• 1.4.8.1.1 Research and Clinical
  Development.......................................
  ................................. 49
• 1.4.8.1.2 Commercial Operation and Access
  ..................................................
  ....................... 49
• Navigating Crisis Recovery and Looking to the
  Future...................................... 50
• 2. Industry Analysis .............................
  .........................................51
• 2.1 Overview......................................
  ..................................................
  ...................52
• 2.2 Legal Requirements and Frameworks in the
  U.S..........................................52
  2.2.1 Clinical Trial Authorization
  ..................................................
  .......................52
• 2.2.2 Marketing Authorization
  ..................................................
  ...........................52
• 2.2.3 U.S. Food and Drug Administration
  Guidelines for Biologics License Application
  (BLA) ............................................
  ..............................54
• 2.2.4 Post-Authorization Regulations
  ..................................................
  ...............55

Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
4
5
3.4 Market Restraints.............................
..................................................
..............66 3.4.1 High Treatment Cost
Impacting the Adoption Rate.......................
...........66 3.4.2 Increased Delay in
Diagnosis ........................................
.............................67 3.5 Market
Opportunities.....................................
..................................................
68 3.5.1 Massive Scope in Emerging
Markets...........................................
..............68 4. Competitive Landscape
..................................................
...........70 4.1 Overview........................
..................................................
.................................71 4.2 Key
Developments and Strategies ......................
...........................................72 4.2.
1 Regulatory and Legal Activities
..................................................
...............73 4.2.2 Product Approvals
..................................................
....................................74 4.2.3
Partnerships and Alliances .......................
.................................................7
5 4.2.4 Merger and Acquisition
Activities........................................
......................76 4.3 Market Share
Analysis, by Company (2021).......................
...........................77 4.4 Growth Share
Analysis .........................................
..........................................78 5. Gl
obal Axial Spondyloarthritis Market (by
Commercialized Therapies), Million, 2021-2032
.................................................8
0 5.1 Overview....................................
..................................................
.....................81 5.2 Anti-Tumor Necrosis
Factor (TNF) Therapy .............................
.....................82 5.2.1 Cimzia
(Certolizumab Pegol) .............................
.........................................82 5.2.1.
1 Cimzia for Indication 1 (Ankylosing
Spondylitis) .....................................
........... 83 5.2.1.2 Cimzia for Indication 2
(Non-radiographic Axial Spondyloarthritis)........
............ 84 5.2.2 Simponi (Golimumab)
..................................................
...............................85
5.2.2.1 Simponi for Indication 1 (Ankylosing
Spondylitis) .....................................
......... 86 5.2.2.1.1 Simponi as Subcutaneous
Formulation ......................................
............................. 86 5.2.2.1.2 Simpon
i AREA as an Intravenous Formulation
..................................................
..... 87 5.2.2.2 Simponi for Indication 2
(Non-radiographic Axial Spondyloarthritis)........
.......... 88 5.3 Anti-Interleukin (IL) Therapy
..................................................
.........................89 5.3.1 Cosentyx
(Secukinumab).....................................
.......................................89
5.3.1.1 Cosentyx for Indication 1 (Ankylosing
Spondylitis) .....................................
....... 90 5.3.1.2 Cosentyx for Indication 2
(Non-radiographic Axial Spondyloarthritis)........
........ 91
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
5
6

• 5.3.2 Taltz (Ixekizumab)........................
  ..................................................
  ..............92
• 5.3.2.1 Taltz for Indication 1 (Ankylosing
  Spondylitis) .....................................
  .............. 93
• 5.3.2.2 Taltz for Indication 2 (Non-radiographic
  Axial Spondyloarthritis) .......................
  94 5.3.3 Lumicef (Brodalumab/KHK4827)............
  ..................................................
  ..95 5.3.3.1 Lumicef for Indication 1
  (Ankylosing Spondylitis) .........................
  ..................... 96
• 5.3.3.2 Lumicef for Indication 2
  (Non-radiographic Axial Spondyloarthritis)
  .................. 97 5.4 Anti-Janus Kinase
  (JAK) Therapy ....................................
  ..............................98 5.4.1
  Xeljanz/Xeljanz XR (Tofacitinib)
  ..................................................
  ...............98
• 6. Global Axial Spondyloarthritis Market (by
  Potential Pipeline Products), Million,
  2021-2032.........................................
  ........ 100
• 6.1 Overview......................................
  ..................................................
  .................101
• 6.2 Anti-Janus Kinase (JAK) Therapy
  ..................................................
  ..............102
• 6.2.1 Rinvoq (Upadacitinib) ....................
  ..................................................
  .........103
• 6.2.2 SHR0302....................................
  ..................................................
  ...............105
• 6.3 Anti-Interleukin (IL)-17 Therapy..............
  ..................................................
  ....107
• 6.3.1 Bimzelx (Bimekizumab) ....................
  ..................................................
  ......107
• 6.3.1.1 Bimzelx for Indication 1 (Ankylosing
  Spondylitis) .....................................
  ....... 108
• 6.3.1.2 Bimzelx for Indication 2
  (Non-radiographic Axial Spondyloarthritis)
  ................ 110 6.4 Other Therapy
  ..................................................
  ..............................................112
  6.4.1 IZN-101 (Namilumab)........................
  ..................................................
  .......113 6.4.2 Otezla (Apremilast)...........
  ..................................................
  .......................115
• Global Axial Spondyloarthritis Market (by
  Indication), Million, 2021-2032.................
  ..................................................
  ............. 117
• 7.1 Overview......................................
  ..................................................
  .................118
• 7.1.1 Ankylosing Spondylitis....................
  ..................................................
  .......119
• 7.1.2 Non-radiographic Axial Spondyloarthritis
  ..............................................120
• Global Axial Spondyloarthritis Market (by
  Country), Million, 2021-2032....................
  ..................................................
  .......... 123
• 8.1 Overview......................................
  ..................................................
  .................124

Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
6
7
8.1.3 Commercialized Products in Japan
..................................................
.......126 8.2 U.S................................
..................................................
.................................127 8.3 Germany
..................................................
..................................................
.....128 8.4 France ..............................
..................................................
.............................129 8.5 U.K.
..................................................
..................................................
.............130 8.6 Italy .......................
..................................................
........................................131 8.7 Sp
ain ..............................................
..................................................
...............132 8.8 Japan .....................
..................................................
.......................................133 9. Comp
any Profiles......................................
...............................
134 9.1 Overview..................................
..................................................
.....................135 9.2 AbbVie Inc.
..................................................
..................................................
.136 9.2.1 Company Overview ....................
..................................................
.............136 9.2.2 Role of AbbVie Inc. in the
Global Axial Spondyloarthritis Market.........136
9.2.3 Financials ................................
..................................................
.................137 9.2.4 Key Insights About
Financial Health of the Company
...........................139 9.2.5 SWOT
Analysis .........................................
.................................................1
40 9.3 Amgen Inc. ................................
..................................................
...................141 9.3.1 Company Overview
..................................................
.................................141 9.3.2 Role
of Amgen Inc. in the Global Axial
Spondyloarthritis Market.........141 9.3.3
Financials .......................................
..................................................
..........142 9.3.4 Key Insights About
Financial Health of the Company
...........................143 9.3.5 SWOT
Analysis .........................................
.................................................1
44 9.4 Bristol-Myers Squibb Company
..................................................
.................145 9.4.1 Company Overview
..................................................
.................................145 9.4.2 Role
of Bristol-Myers Squibb Company in the Global
Axial Spondyloarthritis Market
..................................................
........................145 9.4.3 Financials
..................................................
.................................................1
46 9.4.4 Key Insights About Financial Health of
the Company ...........................147 9.4.5
SWOT Analysis ...................................
..................................................
.....148 9.5 Eli Lilly and Company
..................................................
.................................149
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
7
8
9.5.1 Company Overview .........................
..................................................
........149 9.5.2 Role of Eli Lilly and Company
in the Global Axial Spondyloarthritis
Market............................................
..................................................
...........149 9.5.3 Financials
..................................................
.................................................1
51 9.5.4 Key Insights About Financial Health of
the Company ...........................152 9.5.5
SWOT Analysis ....................................
..................................................
....153 9.6 FunPep Co., Ltd., ...................
..................................................
......................154 9.6.1 Company Overview
..................................................
.................................154 9.6.2 Role
of FunPep Co., Ltd., in the Global Axial
Spondyloarthritis Market.........................
..................................................
..............................154 9.6.3 SWOT
Analysis .........................................
.................................................1
55 9.7 Johnson Johnson Services, Inc.
..................................................
............156 9.7.1 Company Overview
..................................................
.................................156 9.7.2 Role
of Johnson Johnson Services, Inc. in the Global
Axial Spondyloarthritis Market
..................................................
........................156 9.7.3 Financials
..................................................
.................................................1
58 9.7.4 Key Insights About Financial Health of
the Company ...........................160 9.7.5
SWOT Analysis ..................................
..................................................
......161 9.8 Kyowa Kirin Co., Ltd................
..................................................
....................162 9.8.1 Company Overview
..................................................
.................................162 9.8.2 Role
of Kyowa Kirin Co., Ltd. in the Global Axial
Spondyloarthritis Market.........................
..................................................
..............................162 9.8.3
Financials .......................................
..................................................
..........163 9.8.4 Key Insights About Financial
Health of the Company ...........................1
65 9.8.5 SWOT Analysis ........................
..................................................
................166 9.9 Merck Co.,
Inc...............................................
..............................................167
9.9.1 Company Overview .........................
..................................................
........167 9.9.2 Role of Merck Co., Inc. in
the Global Axial Spondyloarthritis
Market............................................
..................................................
...........167 9.9.3 Financials
..................................................
.................................................1
69 9.9.4 Key Insights About Financial Health of
the Company ...........................171
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
8
9
9.9.5 SWOT Analysis ............................
..................................................
............172 9.10 Novartis International
AG................................................
..............................173 9.10.1 Company
Overview .........................................
..........................................173 9.10
.2 Role of Novartis International AG in the Global
Axial Spondyloarthritis Market
..................................................
........................173 9.10.3 Financials
..................................................
.................................................1
75 9.10.4 Key Insights About Financial Health of
the Company ...........................177 9.10.5
SWOT Analysis ....................................
..................................................
....178 9.11 Pfizer Inc...........................
..................................................
............................179 9.11.1 Company
Overview .........................................
..........................................179 9.11
.2 Role of Pfizer Inc. in the Global Axial
Spondyloarthritis Market ...........179 9.11.3
Financials .......................................
..................................................
..........181 9.11.4 Key Insights About Financial
Health of the Company ...........................1
82 9.11.5 SWOT Analysis ..........................
..................................................
..............183 9.12 Takeda Pharmaceutical
Company Limited ..................................
................184 9.12.1 Company Overview
..................................................
.................................184 9.12.2 Role
of Takeda Pharmaceutical Company Limited in the
Global Axial Spondyloarthritis Market.............
..................................................
..184 9.12.3 Financials ..........................
..................................................
.......................185 9.12.4 Key Insights
About Financial Health of the Company
...........................187 9.12.5 SWOT
Analysis .........................................
.................................................1
88 9.13 UCB S.A. .................................
..................................................
......................189 9.13.1 Company Overview
..................................................
.................................189 9.13.2 Role
of UCB S.A. in the Global Axial Spondyloarthritis
Market ............189 9.13.3 Financials
..................................................
.................................................1
91 9.13.4 Key Insights About Financial Health of
the Company ...........................192
9.13.5 SWOT Analysis .............................
..................................................
...........193
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
9
10
List of Figures
Figure 1 Figure 2 Figure 3
Axial Spondyloarthritis Drugs Approved by U.S.
FDA (2015-2021) Axial Spondyloarthritis Drugs
Global Clinical Trials (by Phase) Global Axial
Spondyloarthritis Market (by Commercialized
Therapies), Million, 2021- 2032 Global Axial
Spondyloarthritis Market Impact Analysis Global
Axial Spondyloarthritis Market (by Potential
Pipeline Products), Million, 2021- 2032 Global
Axial Spondyloarthritis Market (by Indication),
Million, 2021-2032 Global Axial
Spondyloarthritis Market (by Country), Million,
2021-2032 Global Axial Spondyloarthritis Market
Segmentation Global Axial Spondyloarthritis
Market Methodology Primary Research
Methodology Bottom-Up Approach (Segment-Wise
Analysis) Step by Step Approach Global Axial
Spondyloarthritis Market, Million, 2021-2032
Evolution of Axial Spondyloarthritis
(axSpA) Treatment Plan for Axial
Spondyloarthritis Complications with Tumor
Necrosis Factor (TNF) Inhibitors Complications
with Interleukin (IL)-17 Inhibitors Complications
with Janus Kinase (JAK) Inhibitors Treatment
Guidelines for Axial Spondyloarthritis,
U.S. Assessment of Spondyloarthritis
International Society (ASAS) and The European
League Against Rheumatism (EULAR) Recommendations
for the Management of Axial Spondyloarthritis
(axSpA) Assessment of Spondyloarthritis
International Society (ASAS) and The European
League Against Rheumatism (EULAR) 13
Recommendations Types of Axial Spondyloarthritis A
xial Spondyloarthritis Prevalence (U.S. EU4
U.K. Japan), 2020-2032 Axial Spondyloarthritis
Prevalence in the U.S., 2020-2032 Percentage of
Axial Spondyloarthritis Prevalence (by Country),
2020 Axial Spondyloarthritis Prevalence in the
EU4 U.K., 2020-2032 Axial Spondyloarthritis
Prevalence in Japan, 2020-2032 Axial
Spondyloarthritis Emerging Therapies
Developmental Phases Key Steps to Navigate
Crisis Recovery Clinical Trial Authorization for
Axial Spondyloarthritis Therapeutics Process for
Obtaining Marketing Authorization U.S. Food and
Drug Administration Review Timeline EMA Review
Timeline Current Reimbursement Scenario in Europe
Figure 4 Figure 5
Figure 6 Figure 7 Figure 8 Figure 9 Figure
10 Figure 11 Figure 12 Figure 13 Figure
14 Figure 15 Figure 16 Figure 17 Figure
18 Figure 19 Figure 20
Figure 21
Figure 22 Figure 23 Figure 24 Figure
25 Figure 26 Figure 27 Figure 28 Figure
29 Figure 30 Figure 31 Figure 32 Figure
33 Figure 34
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
10
11
Figure 35 Figure 36 Figure 37 Figure
38 Figure 39 Figure 40 Figure 41 Figure
42 Figure 43 Figure 44
Number of Clinical Trials for Axial
Spondyloarthritis (by Major Players) Factors
Responsible for Delayed Diagnosis in Axial
Spondyloarthritis Share of Key Developments and
Strategies, January 2019-February 2022
Regulatory and Legal Activities (by Company),
January 2019 to February Product Approvals (by
Company), January 2019 and February
2022 Partnerships and Alliances (by Company),
January 2019 and February 2022 Merger and
Acquisition Activities (by Company), January 2019
and February 2022 Market Share Analysis (by
Company), 2021 Growth Share Matrix for Global
Axial Spondyloarthritis Market (by Company),
2021 Global Axial Spondyloarthritis Market (by
Commercialized Therapies), Million, 2021-
2032 Global Axial Spondyloarthritis Market (by
Anti-Tumor Necrosis Factor (TNF)
Therapy), Million, 2021-2032 Global Revenue for
Cimzia, Million, 2021-2032 Global Revenue for
Cimzia (Ankylosing Spondylitis), Million,
2021-2032 Global Revenue for Cimzia
(Non-radiographic Axial Spondyloarthritis),
Million, 2021- 2032 Global Revenue for Simponi,
Million, 2021-2032 Global Revenue for Simponi
(Ankylosing Spondylitis), Million, 2021-2032
Global Revenue for Simponi AREA (Ankylosing
Spondylitis), Million, 2021-2032 Global Revenue
for Simponi (Non-radiographic Axial
Spondyloarthritis), Million, 2021- 2032 Global
Axial Spondyloarthritis Market (by
Anti-Interleukin (IL) Therapy), Million, 2021-
2032 Global Revenue for Cosentyx, Million,
2021-2032 Global Revenue for Cosentyx (Ankylosing
Spondylitis), Million, 2021-2032 Global Revenue
for Cosentyx (Non-radiographic Axial
Spondyloarthritis), Million, 2021- 2032 Global
Revenue for Taltz, Million, 2021-2032 Global
Revenue for Taltz (Ankylosing Spondylitis),
Million, 2021-2032 Global Revenue for Taltz
(Non-radiographic Axial Spondyloarthritis),
Million, 2021-2032 Global Revenue for Lumicef,
Million, 2021-2032 Global Revenue for Lumicef
(Ankylosing Spondylitis), Million,
2021-2032 Global Revenue for Lumicef
(Non-radiographic Axial Spondyloarthritis),
Million, 2021- 2032 Global Revenue for
Xeljanz/Xeljanz XR, Million, 2021-2032 Global
Axial Spondyloarthritis Market (by Potential
Pipeline Products), Million, 2021- 2032 Global
Axial Spondyloarthritis Market (by Potential
Pipeline Products), by Anti-Janus Kinase
Therapy), Million, 2021-2032 Global Revenue for
Rinvoq, Million, 2021-2032 Upadaticinib Phase
III Clinical Trial Design for Non-radiographic
Axial Spondyloarthritis Global Revenue for
SHR0302, Million, 2021-2032
Figure 45
Figure 46 Figure 47 Figure 48
Figure 49 Figure 50 Figure 51 Figure 52
Figure 53
Figure 54 Figure 55 Figure 56
Figure 57 Figure 58 Figure 59 Figure
60 Figure 61 Figure 62
Figure 63 Figure 64
Axial Spondyloarthritis Market
Figure 65
Figure 66 Figure 67 Figure 68
All rights reserved at BIS Research Inc.
11
12
Figure 69 Figure 70 Figure 71 Figure
72 Figure 73
SHR0302 Phase II/ Phase III Clinical Trial Design
for Ankylosing Spondylitis Global Revenue for
Bimzelx, Million, 2021-2032 Global Revenue for
Bimzelx (Ankylosing Spondylitis), Million,
2021-2032 Bimzelx Phase III Clinical Trial
Design for Ankylosing Spondylitis Global Revenue
for Bimzelx (Non-radiographic Axial
Spondyloarthritis), Million, 2021- 2032 Bimzelx
Phase III Clinical Trial Design for
Non-radiographic Axial Spondyloarthritis Global
Axial Spondyloarthritis Market (by Potential
Pipeline Products), by Other Therapy), Million,
2021-2032 Global Revenue for IZN-101, Million,
2021-2032 IZN-101 Phase II Clinical Trial Design
for Axial Spondyloarthritis Global Revenue for
Otezla, Million, 2021-2032 Otezla Phase III
Clinical Trial Design for Ankylosing
Spondylitis Global Axial Spondyloarthritis Market
(by Indication), Million, 2021-2032 Global Axial
Spondyloarthritis Market (by Indication, by
Ankylosing Spondylitis), Million,
2021-2032 Global Axial Spondyloarthritis Market
(by Indication, by Non-Radiographic Axial
Spondyloarthritis), Million, 2021-2032 Global
Axial Spondyloarthritis Market (by Country),
Million, 2021-2032 U.S. Axial Spondyloarthritis
Market, Million, 2021-2032 Germany Axial
Spondyloarthritis Market, Million, 2021-2032
France Axial Spondyloarthritis Market, Million,
2021-2032 U.K. Axial Spondyloarthritis Market,
Million, 2021-2032 Italy Axial
Spondyloarthritis Market, Million, 2021-2032
Spain Axial Spondyloarthritis Market, Million,
2021-2032 Japan Axial Spondyloarthritis Market,
Million, 2021-2032 Total Number of Companies
Profiled AbbVie Inc. Pre-Clinical and Clinical
Assets AbbVie Inc. Overall Financials,
Million, 2019-2021 AbbVie, Inc. Revenue (by
Region), Million, 2019-2021 AbbVie Inc. RD
Expenditure, Million, 2019-2021 AbbVie Inc.
SWOT Analysis Amgen Inc. Pre-Clinical and
Clinical Assets Amgen Inc. Overall Financials,
Million, 2019-2021 Amgen Inc. Revenue (by
Region), Million, 2019-2021 Amgen Inc. RD
Expenditure, Million, 2019-2021 Amgen Inc. SWOT
Analysis Bristol-Myers Squibb Company
Pre-Clinical and Clinical Assets Bristol-Myers
Squibb Company Overall Financials, Million,
2019-2021 Bristol-Myers Squibb Company Revenue
(by Region), Million, 2019-2021 Bristol-Myers
Squibb Company RD Expenditure, Million,
2019-2021
Figure 74 Figure 75
Figure 76 Figure 77 Figure 78 Figure
79 Figure 80 Figure 81
Figure 82
Figure 83 Figure 84 Figure 85 Figure
86 Figure 87 Figure 88 Figure 89 Figure
90 Figure 91 Figure 92 Figure 93 Figure
94 Figure 95 Figure 96 Figure 97 Figure
98 Figure 99 Figure 100 Figure 101 Figure
102 Figure 103 Figure 104 Figure 105
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
12
13
Figure 106 Figure 107 Figure 108 Figure
109 Figure 110 Figure 111 Figure 112 Figure
113 Figure 114 Figure 115 Figure 116 Figure
117 Figure 118 Figure 119 Figure 120 Figure
121 Figure 122 Figure 123 Figure 124 Figure
125 Figure 126 Figure 127 Figure 128 Figure
129 Figure 130 Figure 131 Figure 132 Figure
133 Figure 134 Figure 135 Figure 136 Figure
137 Figure 138 Figure 139 Figure 140 Figure
141 Figure 142 Figure 143 Figure 144
Bristol-Myers Squibb Company SWOT Analysis Eli
Lilly and Company Commercialized Therapy Eli
Lilly and Company Overall Financials, Million,
2019-2021 Eli Lilly and Company Revenue (by
Region), Million, 2019-2021 Eli Lilly and
Company RD Expenditure, Million, 2019-2021 Eli
Lilly and Company SWOT Analysis FunPep Co.,
Ltd. Pre-Clinical and Clinical Assets FunPep
Co., Ltd. SWOT Analysis Johnson Johnson
Services, Inc. Commercialized Therapy Johnson
Johnson Services, Inc. Overall Financials,
Million, 2019-2021 Johnson Johnson Services,
Inc. Revenue (by Segment), Million, 2019-2021
Johnson Johnson Services, Inc. Revenue (by
Region), Million, 2019-2021 Johnson Johnson
Services, Inc. RD Expenditure, Million,
2019-2021 Johnson Johnson Services, Inc. SWOT
Analysis Kyowa Kirin Co., Ltd. Commercialized
Therapy Kyowa Kirin Co., Ltd. Overall Financials,
Million, 2019-2021 Kyowa Kirin Co., Ltd.
Revenue (by Region), Million, 2019-2021 Kyowa
Kirin Co., Ltd. RD Expenditure, Million,
2019-2021 Kyowa Kirin Co., Ltd. SWOT
Analysis Merck Co., Inc. Commercialized
Therapy Merck Co., Inc. Overall Financials,
Million, 2019-2021 Merck Co., Inc. Revenue
(by Segment), Million, 2019-2021 Merck Co.,
Inc. Revenue (by Region), Million, 2019-2021
Merck Co., Inc. RD Expenditure, Million,
2019-2021 Merck Co., Inc. SWOT
Analysis Novartis International AG
Commercialized Therapy Novartis International AG
Overall Financials, Million, 2019-2021 Novartis
International AG Revenue (by Segment), Million,
2019-2021 Novartis International AG Revenue (by
Region), Million, 2019-2021 Novartis
International AG RD Expenditure, Million,
2019-2021 Novartis International AG SWOT
Analysis Pfizer Inc. Commercialized
Therapy Pfizer Inc. Overall Financials,
Million, 2019-2021 Pfizer Inc. Revenue (by
Region), Million, 2019-2021 Pfizer Inc. RD
Expenditure, Million, 2019-2021 Pfizer Inc.
SWOT Analysis Takeda Pharmaceutical Company
Limited Pre-Clinical and Clinical Assets Takeda
Pharmaceutical Company Limited Overall
Financials, Million, 2018-2020 Takeda
Pharmaceutical Company Limited Revenue (by
Region), Million, 2018-2020
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
13
14
Figure 145 Figure 146 Figure 147 Figure
148 Figure 149 Figure 150 Figure 151 Figure
152
Takeda Pharmaceutical Company Limited RD
Expenditure, Million, 2018-2020 Takeda
Pharmaceutical Company Limited SWOT Analysis UCB
S.A. Commercialized Therapy UCB S.A.
Pre-Clinical and Clinical Assets UCB S.A.
Overall Financials, Million, 2019-2021 UCB
S.A. Revenue (by Region), Million,
2019-2021 UCB S.A. RD Expenditure, Million,
2019-2021 UCB S.A. SWOT Analysis
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
14
15
List of Tables
Table 1 Table 2 Table 3 Table 4 Table
5 Table 6 Table 7 Table 8 Table 9 Table
10 Table 11 Table 12 Table 13 Table 14 Table
15 Table 16 Table 17 Table 18
Annual Cost of Approved Axial Spondyloarthritis
Therapeutics in U.S. Likert Scale Impact
Analysis of Market Drivers Impact Analysis of
Market Restraints Approved Biologic Agents for
Axial Spondyloarthritis (axSpA), (2020-2021)
Approved Axial Spondyloarthritis Products in
Developed Nations Axial Spondyloarthritis Drugs
for Ankylosing Spondylitis Axial
Spondyloarthritis Drugs for Non-radiographic
Axial Spondyloarthritis List of Selective Axial
Spondyloarthritis Commercialized Products in the
U.S. List of Selective Axial Spondyloarthritis
Commercialized Products in the EU4 U.K. List
of Selective Axial Spondyloarthritis
Commercialized Products in Japan Taltz
(Ixekizumab) Indications Simponi/Simponi Area
(Golimumab) Indications Lumicef
(Brodalumab/KHK4827) Indications Simponi
(Golimumab) Indications Cosentyx (Secukinumab)
Indications Xeljanz/Xeljanz XR
Indications Cimzia (Certolizumab Pegol)
Indications
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
15
16
BIS Research Offerings
We are on a mission to harness the potential of
disruptive technologies to make businesses thrive
in todays digital age. We have a vision to be a
leading and a preferred knowledge partner for
corporates and institutions worldwide and assist
them with market intelligence in the area of
emerging technologies, advisories, and other
innovative solutions.
Know More
Know More
Know More
Axial Spondyloarthritis Market
Know More
All rights reserved at BIS Research Inc.
16
17
Disclaimer
BIS Research Inc. provides valuable market
intelligence to an exclusive group of customers
in response to orders. The report is licensed
for the customer's internal use only and is
subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings.
Market reports are based on expectations,
estimates, and projections as of the date such
information is available. Any recommendation
contained in this report may not be suitable for
all investors or businesses. The market
conclusions drawn are necessarily based upon a
number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of
the date of such statements, are inherently
subject to market fluctuations and business,
economic and competitive uncertainties and
contingencies.
For more details regarding permission, please
contact us Email sales_at_bisresearch.com Tel 1
510 404 8135
Axial Spondyloarthritis Market
All rights reserved at BIS Research Inc.
17
18
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
t e k r a M s i t i r h t r a o l y d n
o p S l a i x All rights reserved at BIS
Research Inc. 18 A
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
www.bisresearch.com